Last reviewed · How we verify

CSL312 — Competitive Intelligence Brief

CSL312 (CSL312) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: apoA-I mimetic. Area: Cardiovascular.

phase 3 apoA-I mimetic Apolipoprotein A-I pathway; ABCA1 transporter Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

CSL312 (CSL312) — CSL Behring. CSL312 is an apolipoprotein A-I (apoA-I) mimetic that increases HDL cholesterol and promotes reverse cholesterol transport.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CSL312 TARGET CSL312 CSL Behring phase 3 apoA-I mimetic Apolipoprotein A-I pathway; ABCA1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (apoA-I mimetic class)

  1. CSL Behring · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CSL312 — Competitive Intelligence Brief. https://druglandscape.com/ci/csl312. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: